Research Labs

Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.

Radiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.

Dr. Yueming Li studies disease mechanism of Cancer and Alzheimer’s, with the goal of developing novel therapeutics for clinical use.

The Lima laboratory studies mechanisms underlying RNA processing as well as post-translational protein modification by ubiquitin-like proteins.

The Long laboratory investigates the molecular mechanisms of ion channels and enzymatic membrane proteins and seeks to use these discoveries to benefit humanity.

Chemical Biologist Minkui Luo develops cutting-edge tools, technologies and concepts to annotate functions of protein-posttranslational modifications and designs inhibitors for cancer therapies.

Molecular geneticist Elli Papaemmanouil performs systematic interrogations of well-annotated clinical trial cohorts in leukemia and cancer to explore how the compound genetic and clonal architecture in patients' leukemias and tumors dictate clinical phenotype, disease progression, and clinical outcomes.

The Patel laboratory studies the structural biology of macromolecular recognition, regulation and catalysis. Ongoing projects include structure-function studies of the CRISPR-Cas and cGAS-STING surveillance pathways, on the role of Structure Maintenance Chromosome complexes in mediating DNA double strand break repair, on the role of histone and DNA methylation in epigenetic regulation and on RNA-mediated processes ranging from riboswitches and ribozymes to those governing siRNA and piRNA pathways.

The Pavletich laboratory studies the structural biology of pathways that control cell growth and maintain the integrity of the genome.

Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.